Position in NCNA
as of Jun 30, 2026
· filed Aug 12, 2026
Position Value
$7,140
+$1,930 QoQ
Shares Held
4,698
+26.2% QoQ
Ownership
0.113%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
#5
of 10 holders
Holding Since
Sep 2024
8 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in NCNA Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Jun 30, 2026RHUMBLINE ADVISERS holds $1,414,750,230 across 330 Biotechnology names. NCNA ranks #317 (0.0% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | VRTX |
Vertex Pharmaceuticals Inc / Ma
|
396,380 | $196,893,837 | |
| 2 | REGN |
Regeneron Pharmaceuticals, Inc.
|
157,794 | $98,390,870 | |
| 3 | MRNA |
Moderna, Inc.
|
809,853 | $56,714,005 | |
| 4 | ALNY |
Alnylam Pharmaceuticals, Inc.
|
165,579 | $49,844,246 | |
| 5 | INCY |
Incyte Corp
|
428,533 | $48,578,500 | |
| 6 | RVMD |
Revolution Medicines, Inc.
|
226,008 | $42,326,778 | |
| 7 | ROIV |
Roivant Sciences Ltd.
|
1,178,789 | $41,717,342 | |
| 8 | JAZZ |
Jazz Pharmaceuticals plc
|
163,018 | $39,282,447 |
All Filings in NCNA
Export CSV
8 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $7,140 | 4,698 | Shares | Sole | 2026-08-12 | |
| 2026-03-31 | $5,210 | 3,722 | Shares | Sole | 2026-05-12 | |
| 2025-12-31 | $17,672 | 4,909 | Shares | Sole | 2026-02-13 | |
| 2025-09-30 | $2,296 | 495 | Shares | Sole | 2025-11-06 | |
| 2025-06-30 | $460 | 8,072 | Shares | Sole | 2025-08-12 | |
| 2025-03-31 | $1,590 | 1,822 | Shares | Sole | 2025-05-29 | |
| 2024-12-31 | $1,600 | 1,345 | Shares | Sole | 2025-05-29 | |
| 2024-09-30 | $2,592 | 1,127 | Shares | Sole | 2024-11-12 | |
| No filing history on record for this holder in this stock. | ||||||